Clinical Trial Staff definition

Clinical Trial Staff shall have the meaning as set forth in Clause 2.1. “Confidential Information” shall have the meaning as set forth in Clause 10.1. “Data Controller” shall mean the natural or legal person, public authority, agency or any other body which alone or jointly with others determines the purposes and means of the processing of personal data. “Data Processor” shall mean a natural or legal person, public authority, agency or any other body which processes personal data on behalf of the controller. “eCRFs” shall mean the electronic Case Report Forms. “Effective Date” shall have the meaning as set forth above. “ICH GCP” shall mean the ICH Guidelines for Good Clinical Practice ”Indemnifiable Losses” shall have the meaning as set forth in Clause 12.1. “Institution” shall have the meaning as set forth above. “Institution Indemnitees” shall have the meaning as set forth in Clause 12.1. “Inventions” shall have the meaning as set forth in Clause 9.2. “Investigational Product” shall mean the investigational product as set forth above. “Investigator” shall have the meaning as set forth in Clause 1.3. “Materials” shall have the meaning as set forth in Clause 5.1. “Personal Data” shall mean any information relating to an identified or identifiable natural person. “Process” and “Processing” shall mean any operation or set of operations which is performed upon Personal Data, whether or not by automatic means, such as collection, recording, organization, storage, adaptation or alteration, retrieval, consultation, use, disclosure by transmission, dissemination or otherwise making available, alignment or combination, blocking, erasure or Pod pojmem „identifikovatelná osoba“ se rozumí každá osoba, kterou lze přímo nebo nepřímo identifikovat zejména odkazem na její identifikační číslo nebo na jeden či více faktorů specifických pro její fyzickou, fyziologickou, duševní, ekonomickou, kulturní nebo společenskou identitu. Pod pojmem „platné zákony a požadavky“ se rozumí význam uvedený v odstavci 1.2. Pod pojmem „klinické hodnocení“ se rozumí klinické hodnocení, jak je uvedeno výše. Pod pojmem „personál klinického hodnocení“ se rozumí význam uvedený v odstavci 2.1. Pod pojmem „důvěrné informace“ se rozumí význam uvedený v odstavci 10.1. Pod pojmem „správce údajů“ se rozumí fyzická nebo právnická osoba, orgán veřejné moci, agentura nebo jakýkoli jiný subjekt, který sám nebo společně s jinými určuje účely a prostředky zpracování osobních údajů. Pod pojmem „zpracovatel údajů“ se rozumí fyzick...
Sample 1
Clinical Trial Staff shall have the meaning as set forth in Clause 2.1. “Confidential Information” shall have the meaning as set forth in Clause 10.1. “Data Controller” shall mean the natural or legal person, public authority, agency or any other body which alone or jointly with others determines the purposes and means of the processing of personal data. “Data Processor” shall mean a natural or legal person, public authority, agency or any other body which processes personal data on behalf of the controller. “eCRFs” shall mean the electronic Case Report Forms. “Effective Date” shall have the meaning as set forth above. “ICH GCP” shall mean the ICH Guidelines for Good Clinical Practice ”Indemnifiable Losses” shall have the meaning as set forth in Clause 12.1. “Institution” shall have the meaning as set forth above. “Institution Indemnitees” shall have the meaning as set forth in Clause 12.1. “Inventions” shall have the meaning as set forth in Clause 9.2. “Investigational Product” shall mean the investigational product as set forth above. DEFINICE Pro účely této smlouvy mají termíny definované níže význam, který je níže přesně vymezen: Pod pojmem „smlouva“ se rozumí tato smlouva o klinickém hodnocení spolu s přílohami. Jakýkoli odkaz na tuto smlouvu je považován za odkaz na tuto smlouvu včetně jejích příloh. Pod pojmem „identifikovatelná osoba“ se rozumí každá fyzická osoba, kterou lze přímo nebo nepřímo identifikovat, zejména odkazem na její identifikační číslo nebo na jeden či více faktorů specifických pro její fyzickou, fyziologickou, duševní, ekonomickou, kulturní nebo společenskou identitu. Pod pojmem „platné zákony a požadavky“ se rozumí význam uvedený v odstavci 1.2. Pod pojmem „klinické hodnocení“ se rozumí klinické hodnocení, jak je uvedeno výše. Pod pojmem „personál klinického hodnocení“ se rozumí význam uvedený v odstavci 2.1. Pod pojmem „důvěrné informace“ se rozumí význam uvedený v odstavci 10.1. Pod pojmem „správce údajů“ se rozumí fyzická nebo právnická osoba, orgán veřejné moci, agentura nebo jakýkoli jiný subjekt, který sám nebo společně s jinými určuje účely a prostředky zpracování osobních údajů. Pod pojmem „zpracovatel údajů“ se rozumí fyzická nebo právnická osoba, orgán veřejné moci, agentura nebo jakýkoli jiný subjekt, který osobní údaje zpracovává jménem správce. Pod pojmem „formuláře eCRF“ se rozumí elektronické formuláře pro podávání zpráv o případu („záznamy subjektu hodnocení“). Pojem „datum nabytí účinnosti“ má význam uvedený výše. Pod zkratkou „ICH G...
Sample 1

Examples of Clinical Trial Staff in a sentence

  • Clinical Trial Staff: Individuals, identified by the investigator, who are responsible for study coordination, data collection and data management.

  • Investigator and the Clinical Trial Staff must be available to answer questions, discuss corrective measures and to support the work of the monitor.

  • Any monitor shall have direct access to relevant facilities and to all requested trial-related records and documents as well as Investigator and Clinical Trial Staff.

  • In consideration for the work performed by Institution, Investigator and the Clinical Trial Staff under this Agreement, Sponsor shall pay the remuneration as set forth in the budget and in accordance with the payment terms attached in Appendix 1.

  • The delegation of any task of Investigator to any Clinical Trial Staff must be documented in writing prior to the implementation of the delegation.

  • Institution is responsible for ensuring that the Clinical Trial Staff comply with the terms of this Agreement and the Protocol.

  • Institution hereby agree to provide the Investigator and the Clinical Trial Staff with the Privacy Notice, attached hereto as Appendix 2, describing the processing, including collection, use, retention and disclosure of such Personal Data collected by Sponsor.

  • NodeSwap also offers to stack pools for the purpose of helping the community to share its assets.

  • Institution and Investigator are responsible for ensuring that the Clinical Trial Staff comply with the terms of this Agreement and the Protocol.

  • Accordingly, Institution and Investigator hereby agree that prior to and during the course of the Clinical Trial, Sponsor may collect Personal Data relating to the Investigator and the Clinical Trial Staff.

Related to Clinical Trial Staff

  • Clinical staff means persons who work in a hospital whose duties include the personal care or medical treatment of patients. “Clinical staff” includes, but is not limited to, credentialed physicians, physicians’ assistants, nurses, nursing aides, medical technicians, therapists, and other individuals involved in the personal care or medical treatment of patients.

  • Phase 2 Clinical Trial means a human clinical trial, for which the primary endpoints include a determination of dose ranges or an indication of efficacy in patients being studied as described in 21 C.F.R. §312.21(b), or an equivalent clinical trial in a country in the Territory other than the United States.

  • Clinical Trial means any human clinical trial of a Product.

  • Phase 1 Clinical Trial means a Clinical Trial of a Product on sufficient numbers of normal volunteers and/or patients that is designed to establish that such Product is safe for its intended use and to support its continued testing in Phase 2 Clinical Trials. For purposes of this Agreement, ‘initiation’ of a Phase 1 Clinical Trial for a Product means the first dosing of such Product in a human subject in a Phase 1 Clinical Trial.

  • Phase 3 Clinical Trial means a pivotal clinical trial in humans performed to gain evidence with statistical significance of the efficacy of a product in a target population, and to obtain expanded evidence of safety for such product that is needed to evaluate the overall benefit-risk relationship of such product, to form the basis for approval of an NDA and to provide an adequate basis for physician labeling, as described in 21 C.F.R. § 312.21(c) or the corresponding regulation in jurisdictions other than the United States.

  • Phase 4 Clinical Trial means a Clinical Trial of a Product conducted after Regulatory Approval of such Product has been obtained from an appropriate Regulatory Authority, which trial is (a) conducted voluntarily by a Party to enhance marketing or scientific knowledge of the Product, or (b) conducted due to a request or requirement of a Regulatory Authority.

  • Clinical Trials means a controlled study in humans of the safety or efficacy of a Product, and includes, without limitation, such clinical trials as are designed to support expanded labeling or to satisfy the requirements of an Agency in connection with any Product Approval and any other human study used in research and Development of a Product.

  • Phase IIb Clinical Trial means a clinical trial of a Product on sufficient numbers of patients that is designed to provide a preliminary determination of safety and efficacy of such Product in the target patient population over a range of doses and dose regimens.

  • Clinical Study means a Phase I Study, Phase II Study, Phase III Study, as applicable.

  • Phase I Clinical Study means a human clinical study of a product, the principal purpose of which is a preliminary determination of safety in healthy individuals or patients, as described in 21 C.F.R. 312.21(a).

  • Phase I Clinical Trial means a human clinical trial that is intended to initially evaluate the safety and/or pharmacological effect of a Product in subjects or that would otherwise satisfy requirements of 21 C.F.R. 312.21(a), or its foreign equivalent.

  • Pivotal Clinical Trial means a human clinical trial in any country that is prospectively designed to generate data intended to satisfy the requirements of 21 C.F.R. § 312.21(c) (as amended) in the U.S. or a similar clinical study prescribed by a Regulatory Authority from another country, from time to time, pursuant to Applicable Law.

  • Phase II Clinical Study means a human clinical study of a product initiated to determine the safety and efficacy in the target patient population, as described 21 C.F.R. 312.21(b).

  • Phase II Clinical Trial means a controlled human clinical study that would satisfy the requirements of 21 CFR 312.21(b), conducted to study the effectiveness and establish the dose range of a Product for a particular Indication in patients with the disease or condition under study, including a Phase IIA Clinical Study or Phase IIB Clinical Study.

  • Phase III Clinical Trials means a Clinical Trial for the Product on sufficient numbers of patients to generate safety and efficacy data to support Regulatory Approval in the proposed therapeutic indication, conducted in accordance with current good clinical practices and in accordance with a protocol that has been reviewed by the FDA and reflects any comments or concerns raised by the same.

  • Clinical Studies means human clinical trials for a Licensed Product and any other tests and studies for a Licensed Product in human subjects.

  • Phase III Clinical Study means a trial involving administration of a Compound to sufficient numbers of human patients with the goal of establishing that the Compound is safe and efficacious for its intended use, to define warnings, precautions and adverse reactions that are associated with the drug or label expansion of such Compound, and to be considered as a pivotal study for submission of an NDA.

  • Phase III Clinical Trial means a human clinical trial of a product, the design of which is acknowledged by the FDA to be sufficient for such clinical trial to satisfy the requirements of 21 C.F.R. 312.21(c) (as amended or any replacement thereof), or a similar human clinical trial prescribed by the Regulatory Authority in a country other than the United States, the design of which is acknowledged by such Regulatory Authority to be sufficient for such clinical trial to satisfy the requirements of a pivotal efficacy and safety clinical trial.

  • Phase 3 Trial means a human clinical trial of a Product on a sufficient number of subjects that is designed to establish that a pharmaceutical product is safe and efficacious for its intended use, and to determine warnings, precautions and adverse reactions that are associated with such pharmaceutical product in the dosage range to be prescribed, which trial is intended to support Approval of a Product, as described in 21 C.F.R. 312.21(c) for the United States, or a similar clinical study prescribed by the Regulatory Authorities in a foreign country.

  • Phase 2 Trial means a human clinical trial conducted on study subjects with the disease or condition being studied for the principal purpose of achieving a preliminary determination of efficacy or appropriate dosage ranges, as further described in 21 C.F.R. §312.21(b) (including any such clinical study in any country other than the United States).

  • Phase IV Clinical Trial means a product support clinical trial of a Product commenced after receipt of Regulatory Approval in the country where such trial is conducted. A Phase IV Clinical Trial may include epidemiological studies, modeling and pharmacoeconomic studies, and investigator-sponsored clinical trials studying Product that are approved by the JDC and that otherwise fit the foregoing definition.

  • Clinical means having a significant relationship, whether real or potential, direct or indirect, to the actual rendering or outcome of dental care, the practice of dentistry, or the quality of dental care being rendered to a patient;

  • Pivotal Study means (a) a Phase 3 Study that is intended by Celgene to be submitted (together with any other registration trials that are prospectively planned when such Phase 3 Study is initiated) for Regulatory Approval in the U.S. or the EU, or (b) any other clinical study that is designed to establish that a pharmaceutical product is safe and efficacious for its intended use, and to determine warnings, precautions, and adverse reactions that are associated with such pharmaceutical product in the dosage range to be prescribed, which clinical study is a registration trial intended to be sufficient for filing an application for a Regulatory Approval for the Licensed Product in the U.S. or another country or some or all of an extra-national territory, solely as evidenced by the acceptance for filing for a Regulatory Approval for such product after completion of such study.

  • Phase 1 Trial means, with respect to a Licensed Product, a clinical trial (or — in case of a multi-phase clinical trial — those parts of a clinical trial) in line with the provisions of 21CFR312, Section 21 (a).

  • Phase 3 Study means a clinical study of a drug candidate in human patients that incorporates accepted endpoints for confirmation of statistical significance of efficacy and safety with the aim to obtain Regulatory Approval in any country as described in 21 C.F.R. 312.21(c), or a comparable clinical study prescribed by the relevant Regulatory Authority in a country other than the United States. The relevant drug candidate may be administered to patients as a single agent or in combination with other investigational or marketed agents.

  • Phase 1 Study means a clinical study of a drug candidate in human patients with the primary objective of characterizing its safety, tolerability, and pharmacokinetics and identifying a recommended dose and regimen for future studies as described in 21 C.F.R. §312.21(a), or a comparable clinical study prescribed by the relevant Regulatory Authority in a country other than the United States. The drug candidate can be administered to patients as a single agent or in combination with other investigational or marketed agents.